Overview
Intra-Cellular Therapies is a biopharmaceutical company focused on CNS disorders, best known for Caplyta (lumateperone), an FDA-approved treatment for schizophrenia and bipolar depression. Their drug discovery platform targets intracellular signaling pathways in neurons.
More in Neuropharmaceuticals
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💊 Neuropharmaceuticals
Location
New York, USA
Funding
Public · NASDAQ: ITCI
Listed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →